Skip to main content

Infrastructure for Personalized Medicine at Partners HealthCare.

Partners HealthCare Personalized Medicine (PPM) is central in partner systems HealthCare (founded by Massachusetts General Hospital and Brigham and Women's Hospital) whose mission is to utilize genetics and genomics to improve patient care in a cost effective manner.

 PPM consists of five interrelated Equine Clia Kitscomponents: (1) Laboratory of Molecular Medicine (LMM), CLIA laboratories perform genetic testing for patients around the world; (2) Translational Genomics Core (TGC), a core lab provides a platform for researchers Partners genome; (3) Options Biobank, a Biobank samples (DNA, plasma and serum) for 50,000 patients agree Partners; (4) Biobank Portal, IT infrastructure and the viewer to unify genotype, sample, phenotype (validated diagnosis, radiology, and clinical chemistry) of electronic medical records researchers Partners. These components are held together by (5) common IT system that brings researchers, clinicians, and patients together for optimal research and patient care.
Infrastructure for Personalized Medicine at Partners HealthCare.

Monitoring the process of measles elimination by serosurveillance data: The study Apulian 2012.


In 2003 Italy adopted a National Plan for the Elimination of Measles and Congenital Rubella, but some outbreaks of measles still occur, as the levels of target coverage (≥ 95%) of newborns General Clia Kits has not currently reached. In order to support the monitoring of measles elimination program, the authors conducted a survey on the seroprevalence of measles among young adults Apulia. This study was conducted from May 2011 to June 2012 among blood donors the Department of Transfusion Medicine General Hospital Policlinico di Bari. Subjects were enrolled by convenience sampling. For each patient enrolled we collect 5 mL serum sample. 

Collected sera were tested by chemiluminescence (CLIA) for anti-measles IgG. We enrolled 1764 subjects; 1362 (77.2%) were male with a mean age of 38.4 ± 11.7 years. Anti-measles IgG titer is >> 16.5UA / mL in 95.1% (95% CI = 94.1 to 96.1) of subjects enrolled with Geometric Mean Titre (GMT) 2.3 ± 0.4, which is not divide different registered till the age groups. As our data show, the universal routine vaccinations changing epidemiological pattern in adults, particularly young adults (18-24 years), which indicates the level of the lowest seropositivity; in groups of people there is a risk of outbreaks because of the presence of vulnerable population. 

It is a paradox associated with vaccination strategy: when the level of coverage keep sub-optimal, measles is more likely to affect young adults and a higher percentage of complications are expected. According to our data, health authorities should plan mop-up strategy to actively offer measles vaccination for young adults who are vulnerable.
Labels:

Comments

Post a Comment

Popular posts from this blog

Incidence of the 22q11.2 deletion in a large cohort of miscarriage samples.

BACKGROUND The 22q11.2 deletion syndrome is the most common microdeletion syndrome in live births, but data on the incidence in other populations is limited and also includes ascertainment bias. This study was designed to determine the incidence of miscarriage deletion 22q11.2  Human Clia Kits in samples sent for testing clinical molecular cytogenetics. RESULTS 6101 Twenty fresh products of conception (POC) samples were sent to CLIA- certified, CAP-accredited laboratory of April 2010 - May 2016 for miscarriage molecular cytogenetic testing using single nucleotide polymorphism (SNP) based microarray platform. A retrospective review determined 22q11.2 deletion events in this sample set. The results obtained in 22,451 fetuses (86%) cases, which, 15 (0.07%) had a microdeletion at 22q11.2 region (incidence, 1/1497). Of those, 12 (80%) cases were found in a sample of normal at a resolution karyotyping traditional (ie, no chromosomal abnormalities in over 10 Mb in size) and three cases (2...
Post a Comment
Read more

Validation of laboratory-developed molecular assays for infectious diseases.

molecular technology has transformed the way that clinical laboratories to diagnose and manage many infectious diseases. excellent sensitivity, specificity, and speed has made molecular tests an attractive alternative to a culture or enzyme immunoassay methods. Many molecular tests that are commercially available and FDA approved. Others, particularly those tests for analytes  Bovine Clia Kits less common, often laboratory developed. Laboratory tests are also often modify FDA approved for inserting different extraction systems or other types of additional specimens.  The Clinical Laboratory Improvement Amendments (CLIA) federal regulatory standards that require clinical laboratories to establish and document their own performance specifications for laboratory tests developed to ensure accurate results and just before the execution of the test. The performance characteristics to be formed include accuracy, precision, various reported, hose reference, analytical sensitivity an...
Post a Comment
Read more

Advances in hemoglobin A1c point of care technology.

Measurement of hemoglobin A1c (A1C) has long been accepted as the best indicator of glucose control over time. A1C tests for the technology used by both differences in costs (high pressure liquid chromatography) or structure (boronate affinity or immunoassay combined with general chemistry). This technology is commonly used in expensive laboratory instruments. More recently, technology A1C has been put into place care (POC) devices, allowing for the availability  Simian Clia Kits of measurement of A1C, greatly facilitate diabetes care in both specialist and general practice.  A1C POC tests must have acceptable performance, standardization of national reference, the National Glycohemoglobin Standardization Program (NGSP) certification, simple operation without the need for expensive instrumentation, and the Clinical Laboratory Improvement Amendments (CLIA) waiver. CLIA-waived POC technologies including Bio-Rad MicroMat II (distributed by a Cholestech GDX) and Axis-Shield Afi...
Post a Comment
Read more